177Lu-PNT2002 (formerly 177Lu-PSMA-I&T) is a peptide developed by the Technical University Munich and Scintomics. It was labeled also with 68Ga and 111In for respectively PET and SPECT imaging (but also radio-guided surgery), hence creating a PSMA-probes platform. This drug is an alternative to 177Lu-617Vipivotide tetraxetan, but must be considered as a generic. A Phase III trial was initiated in December 2020. The drug could reach the market by 2024 or 2025.
Radiation Type: beta electrons (β–)